|
02 Oct 2019 |
Update on US regulatory review of PT010 in COPD
|
|
02 Oct 2019 |
Sabin Vaccine Institute Receives $20.5 Million From BARDA With Potential of up to $128 Million to Develop Ebola Sudan and Marburg Vaccines
|
|
02 Oct 2019 |
Cabaletta Bio Receives IND Clearance from FDA to Initiate First Clinical Trial of DSG3-CAART in Patients with Mucosal Pemphigus Vulgaris
|
|
02 Oct 2019 |
Evolus Receives Approval for Nuceiva™ in the European Union
|
|
02 Oct 2019 |
Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
|
|
02 Oct 2019 |
NCX 470 met the primary endpoint of non-inferiority and also demonstrated superiority to latanoprost, the U.S. market leader in prostaglandin analog prescriptions, in multiple pre-specified analyses
|
|
02 Oct 2019 |
Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T
|
|
02 Oct 2019 |
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
|
|
01 Oct 2019 |
Sobi to acquire Dova Pharmaceuticals creating a global growth platform in haematology
|
|
01 Oct 2019 |
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers
|
|
01 Oct 2019 |
Numab and Eisai Enter Into a Global Research and Option Agreement to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer
|
|
01 Oct 2019 |
Themis Bioscience and ZIKAVAX Consortium Announce Initiation of Phase 1 Zika Vaccine Trial
|
|
01 Oct 2019 |
Tmunity Announces Exclusive License and Research Collaboration with Children’s Hospital of Philadelphia to Advance GPC2 CAR-T Cell Therapy for Neuroblastoma
|
|
01 Oct 2019 |
Checkmate Pharmaceuticals Announces Dosing of First Patient in a Phase 1b/2 Study in Squamous Cell Carcinoma of the Head and Neck with Lead Investigational Candidate CMP-001
|
|
01 Oct 2019 |
Debiopharm's Novel IAP Antagonist Debio 1143 Achieves Outstanding Phase II Results for High-Risk Head and Neck Cancer Patients
|
|
01 Oct 2019 |
New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab
|
|
01 Oct 2019 |
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
|
|
01 Oct 2019 |
Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations
|
|
01 Oct 2019 |
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
|
|
01 Oct 2019 |
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
|
